Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Statins prove life-saving in patients with acute coronary syndromes

12.05.2006


Analysis finds statins succeed where it matters most—in improving survival



Patients who begin aggressive statin therapy while in the hospital for acute coronary syndromes (ACS) have a significantly greater chance of long-term survival, according to an analysis reported at the Society for Cardiovascular Angiography and Interventions (SCAI) 29th Annual Scientific Sessions in Chicago, May 10–13. (Time of presentation: Thursday, May 11, 11:33 a.m., Central Time)

By combining data from nine randomized clinical trials and evaluating clinical outcomes individually rather than in combination, the analysis was able to put a sharper focus on the benefits of early statin therapy.


"We found that there was a benefit in what matters most--survival," said Anthony Bavry, MD, a fellow in cardiovascular medicine at the Cleveland Clinic Foundation in Cleveland, OH.

The study involved data from more than 16,000 patients admitted to the hospital with ACS, a term that encompasses both unstable chest pain, or angina, and a particular form of heart attack. In each of the original studies, patients were randomly assigned to maximal-dose statin therapy during the hospital stay or to a more conservative approach that consisted of low-dose statin therapy or placebo.

Statins are primarily used to lower cholesterol levels in the blood, but they have other effects as well, including the ability to reduce inflammation in the arteries.

Dr. Bavry and his colleagues found that early, aggressive statin therapy reduced the risk of death by 22 percent and the risk of cardiovascular death by 25 percent, over a follow-up that averaged 15 months. Further analysis showed that for every 111 patients who were treated with early statin therapy, one life could be saved.

In addition, early statin therapy reduced the risk of another episode of unstable angina by 17 percent and the need to open a blocked coronary artery with a catheter-based procedure or coronary bypass surgery by 9 percent.

The improvement in survival was noticeable early on but became statistically certain only after six months of statin therapy. "The benefits keep accruing," Dr. Bavry said. "Once a patient has acute coronary syndrome, there may not be a safe time to discontinue this medication."

Kathy Boyd David | EurekAlert!
Further information:
http://www.scai.org

More articles from Health and Medicine:

nachricht The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>